Purpose of review Congenital hyperinsulinism is the most common cause of persistent hypoglycemia in infants and children. Early and appropriate recognition and treatment of hypoglycemia is vital to minimize neurocognitive impairment.
INTRODUCTION
Congenital hyperinsulinism, the most common cause of persistent hypoglycemia in infants and children, occurs in approximately 1 in 50 000 live births, but the incidence can be as high as 1 in 2500 in populations with high consanguinity rates. Early recognition and management of severe hypoglycemia is necessary to minimize risk of permanent neurologic damage, which is common among individuals with hyperinsulinism [1,2 && ,3 && ]. In 2015, the Pediatric Endocrine Society released recommendations for evaluation and management of persistent hypoglycemia [4] , and sensitive laboratory-based criteria (Table 1) can be used to confirm the diagnosis [5] . Although persistent hypoglycemia in newborns may also result from other causes, including hypopituitarism, our review focuses on monogenic and syndromic forms of hyperinsulinism and their management.
MOLECULAR GENETICS
There are currently at least 11 known monogenic causes of hyperinsulinism [6] . However, a genetic cause remains unknown in approximately 40-50% of affected children even after extensive genetic evaluation [7, 8] . More recently, it has become apparent that in some children, hyperinsulinism is only one feature of more complex syndromes, such as
K ATP hyperinsulinism
The most common and most severe form of hyperinsulinism is due to inactivating mutations in ABCC8 and KCNJ11, which encode the two subunits of the beta-cell ATP-sensitive potassium channel (SUR-1 and Kir6.2, respectively) [9, 10] . K ATP hyperinsulinism is usually unresponsive to diazoxide because of the absence or deficiency of functional K ATP channels. K ATP hyperinsulinism presents in the first few days after birth, and affected infants are born large for gestational age. Recessive K ATP mutations, including missense, nonsense, or splicing defects, lead to diazoxide-unresponsiveness through complete absence of K ATP channels. In contrast, dominant K ATP mutations (missense) lead to mutant K ATP channel subunits that impair channel activity when assembled into the K ATP channel complex, and the degree of diazoxide-responsiveness is determined by the relative impairment in channel activity [11, 12] . Hypoglycemia in K ATP hyperinsulinism occurs in both the fasting state and after protein load, likely because of glutamine-stimulated 'amplification' of GLP-1 receptor signaling [13, 14] .
There are two distinct histological forms of K ATP hyperinsulinism: a diffuse form, in which all pancreatic ß-cells are affected, and a focal form, in which only a small area of the pancreas is affected. Diffuse hyperinsulinism results from biallelic recessive mutations in ABCC8 or KCNJ11 but can also result from dominant mutations. Focal hyperinsulinism, which accounts for approximately 50% of cases of severe hyperinsulinism, is the result of a 'two hit' mechanism: a paternally inherited recessive mutation in ABCC8 or KCNJ11, and somatic loss of the maternal inherited 11p15 chromosomal region in which these genes and tumor-suppressing maternally imprinted genes are encoded, compensated by paternal uniparental disomy [15] . The focal form of K ATP hyperinsulinism can be cured by surgical resection of the lesion; thus, when evaluating children with hyperinsulinism, it is extremely important to identify those that are likely to have focal hyperinsulinism. There are some subtle clinical differences between diffuse and focal cases, but overall it is difficult to predict focal disease from the clinical presentation [16] . However, genetic testing is extremely helpful to predict focal hyperinsulinism: the finding of a single heterozygous recessive mutation in either ABCC8 or KCNJ11 has 94% positive predictive value for focal disease, whereas two recessive K ATP channel mutations predict diffuse disease [7] .
KEY POINTS
Congenital hyperinsulinism should be suspected in neonates with persistent hypoglycemia beyond 48 h of life.
Diazoxide is the first-line medication but is often ineffective in hyperinsulinism due to inactivating mutations in the genes encoding the ATP-sensitive potassium channel (K ATP hyperinsulinism).
Molecular diagnosis may aid in treatment decisions because of the ability to anticipate the likelihood of diazoxide responsiveness and the possibility of focal lesions.
Therapies for hyperinsulinism remain limited. Reproduced with permission from [5] .
There is marked clinical heterogeneity in the clinical presentation and the clinical course of children with K ATP hyperinsulinism [17 & ], and the study of tissue and isolated islets from the pancreas of children who have undergone pancreatectomy is starting to provide some insight into the molecular and cellular mechanisms that may, at least in part, explain this heterogeneity [18
Glutamate dehydrogenase hyperinsulinism Dominant activating mutations in GLUD1, which encodes for the enzyme glutamate dehydrogenase (GDH), give rise to hyperinsulinism/hyperammonemia syndrome, the second most common cause of congenital hyperinsulinism. GDH mediates proteinstimulated insulin secretion through allosteric activation by leucine [20] . The functional impact of the most common GDH mutation, GDH-Ser445Leu, was recently characterized by Grimaldi et al. One recent case report described a functionally homozygous activating mutation of GLUD1 (novel frameshift mutation c.37delC from the asymptomatic mother and a de novo activating mutation p.S445L), which resulted in severe onset hypoglycemia, hyperammonemia, and seizures on the first day of life. In lymphoblasts from the described patient, GTP inhibition of GDH activity led to half-maximal inhibitory concentration (IC50) for GTP that was approximately seven times higher compared with a heterozygote for p.S445L and 200 times wild-type [22 ] . Notably, the patient's phenotype was within the range of severity for a heterozygous GLUD1 mutation. This report was the first of a homozygous activating mutation of GLUD1 in a human.
In addition to fasting hypoglycemia because of hyperinsulinism, hyperinsulinism/hyperammonemia is characterized by hyperammonemia and protein-induced hypoglycemia, and the clinical phenotype correlates with the degree of impaired responsiveness to GTP inhibition [23] . Hyperammonemia occurs because of increased renal ammoniagenesis [24] . Individuals with hyperinsulinism/ FIGURE 1. Beta-cell depicting the impact of known monogenic causes of hyperinsulinism on insulin secretion. Glucose-stimulated insulin secretion is triggered by an increased in ATP/ADP ratio resulting from glucose metabolism. Glucokinase (GCK) is the ß-cell glucose sensor setting the threshold for insulin secretion. The increased in ATP/ADP ratio results in closing of the ATP-sensitive K ATP channels (SUR1/Kir6.2), with subsequent plasma membrane depolarization, activation of voltage-gated calcium channels, cytosolic calcium increase, and insulin release from stored intracellular granules. Eleven known ß-cell genes are responsible for monogenic hyperinsulinism: ABCC8 (encoding sulfonylurea receptor 1, SUR1), KCNJ11 (encoding inwardly rectifying potassium channel 6.2, Kir6.2), GCK (encoding glucokinase), SLC16A1 (encoding monocarboxylate transporter 1, MCT1), FOXA2 (forkhead box A2), HADH (encoding short-chain 3-hydroxyacyl-CoA dehydrogenase, SCHAD), GLUD1 (encoding glutamate dehydrogenase, GDH), PGM1 (encoding phosphoglucomutase 1), HNF1A (hepatocyte nuclear factor 1A), HNF4A (hepatocyte nuclear factor 4A), and UCP2 (uncoupling protein 2). aKG, a-ketoglutarate; Ac-CoA, acetyl-CoA; G6P, glucose 6-phosphate; G-1,6-P, glucose 1,6-bisphosphate; INS, insulin.
hyperammonemia syndrome are diazoxide-responsive, have protein-sensitive hypoglycemia, normal birth weight, and later-onset hypoglycemia (median 4 months) [20] . Hyperammonemia appears asymptomatic and unnecessary to treat [20] . Individuals with hyperinsulinism/hyperammonemia have increased risk of seizures, in particular absence seizures, unrelated to hypoglycemia, as well as higher rates of developmental delay that appear to be independent of hypoglycemic brain damage [25] .
A similar phenotype of fasting and proteininduced hyperinsulinism, but without hyperammonemia, is due to inactivating mutations in HADH, which encodes the mitochondrial enzyme shortchain 3-hydroxyacyl-CoA dehydrogenase, known as SCHAD hyperinsulinism [26] . In addition to its primary role in the catalysis of fatty acid oxidation of medium and short-chain 3-hydroxy fatty acylCoAs, SCHAD is an allosteric inhibitor of GDH [25] . With SCHAD deficiency, loss of GDH inhibition leads to protein-sensitive hyperinsulinism [25, 27] . Camtosun et al. recently reported the long-term clinical course of a patient with a deep intronic HADH splicing mutation (c.636þ471G>T). The patient was macrosomic at birth and was diagnosed with hyperinsulinism at 30 days of life and treated with diazoxide. By the age of 20 years, she continued to require a low dose of diazoxide (2-3 mg/kg/day) to maintain euglycemia [28] . The case highlights the persistence of abnormal glucose and insulin regulation into adulthood.
HNF4A and HNF1A hyperinsulinism
Heterozygous mutations in genes encoding transcription factors hepatocyte nuclear factors 4a or 1a (HNF4A, HNF1A) lead to both congenital hyperinsulinism and subsequent monogenic diabetes [29] [30] [31] [32] . Together, they account for approximately 6% of all diazoxide-responsive cases [33 & ] . Although the precise mechanism by which mutations in HNF4A or HNF1A lead to the phenotypes of both hyperinsulinism and diabetes is unknown, HNF4a binds to the promoters of 11% of islet genes, and its deficiency likely impacts one or more of these downstream targets [32] .
Hyperinsulinism due to HNF4A or HNF1A mutations tends to be diazoxide-responsive [31, 34] , and HNF4A hyperinsulinism represented the third most common cause of hyperinsulinism in a cohort of 220 diazoxide-responsive hyperinsulinism patients studied by Flanagan et al. ]. Using the gnomAD database, Laver et al. found that four of the variants reported as pathogenic, accounting for eight of nine reported patients, were present at high frequency in the dataset. One variant reported in three studies [7, 38, 39 && ], p.Ala268Gly, was present at a frequency in gnomAD that would equate to an incidence of 1 in 128, much higher than the known incidence of 1 in 50 000 in outbred populations. Further evaluation of additional cases will be needed to better understand the functional impact of UCP2 mutations.
MCT1 hyperinsulinism
Mutations in the upstream promoter regions of SLC16A1, which encodes moncarboxylate transporter 1 (MCT1), the pyruvate transporter, have been linked to exercise-induced hypoglycemia [42] . This phenotype results from loss of usual suppression of MCT1 in ß-cells, allowing for insulin secretion in response to pyruvate, which rises with anaerobic exercise [6] .
BeckwithSWiedemann syndrome
The BWS locus on chromosome 11p15.5 includes adjacent imprinted genes that are growth-promoting (IGF2) or growth-inhibitory (noncoding RNA H19 and CDKN1C) [43] . Either hypomethylation of the growth-promoting genes or hypermethylation of the growth-inhibitory genes can result in the phenotype. Twenty percentage of cases are caused by 11p paternal uniparental isodisomy, resulting in both over-expression of IGF2 and no expression of CDKN1C. Approximately 50% of individuals with BWS have hyperinsulinism, with $5% that is severe and persistent, which may be related to expanded ß-cell mass and abnormal ß-cell insulin secretion [43] . As noted by a recent case report of a child with subtle hemihypertrophy and K ATP hyperinsulinism, BWS should be considered in the setting of syndromic features and paternally inherited K ATP channel mutation [44] .
Kabuki syndrome
Kabuki syndrome is the second most common syndromic form of hyperinsulinism, with hyperinsulinism occurring in up to 70% of cases [40 & ]. Kabuki syndrome results from mutations in one of two genes, either autosomal recessive mutations in KMT2D (70-75% of cases) or X-linked mutations in KDM6A (1-9% of cases) [45] . Although the mechanism of hyperinsulinism in Kabuki syndrome is unknown, it appears to be more common in the X-linked form [46] . Unlike BWS-associated hyperinsulinism, most are diazoxide-responsive [6] .
Congenital disorders of glycosylation and related mutations
Congenital disorders of glycosylation (CDG) have a wide phenotypic spectrum, with three identified to be associated with hyperinsulinism: phosphomannomutase 2 (PMM2) deficiency (CDG1a), mannosephosphate isomerase deficiency (CDG1b), and phosphoglucomutase 1 (PGM1) deficiency (CDG1t). CDG1a can present with significant heterogeneity, from single organ involvement presenting as isolated hyperinsulinism to multivisceral failure [47] . Hyperinsulinism associated with CDG1b has been treated with supplemental oral mannose treatment [48, 49] . PGM1 deficiency (CDG1t) also has a wide phenotypic spectrum, which in addition to hyperinsulinemic hypoglycemia includes growth retardation, hepatopathy, dilated cardiomyopathy, hypogonadotropic hypogonadism, myopathy, bifid uvula, and malignant hyperthermia [50] .
Recently, a promoter mutation in PMM2 (c.-167G>T) was identified in 17 children with both hyperinsulinism and congenital polycystic kidney disease from 11 unrelated families [51 & ]. These patients did not exhibit diagnostic features of CDG1a. The authors report that most of the patients were treated with diazoxide and responded, but some did not receive treatment for hypoglycemia. The most common presentation of hyperinsulinism was hypoglycemic seizures, with a median age at hyperinsulinism diagnosis of 10 months of life.
Forkhead box A2 hyperinsulinism
A novel syndrome of hypopituitarism and hyperinsulinism associated with inactivating mutations in the developmental transcription factor forkhead box A2 (Foxa2) was recently described in two reports [52 & ,53 & ]. Both mutations were identified through whole exome sequencing. Described characteristics include single median maxillary central incisor, choroidal coloboma, pulmonary stenosis, persistent oxygen requirement, neuro-developmental delay [52 & ], coarse facial features, hypertelorism, thin upper lip, low set ears, and widely spaced nipples [53 & ]. Foxa2 mRNA is expressed in the developing hypothalamus, pituitary, pancreas, lungs, and esophagus of mouse embryos [52 & ]. Transactivation of target genes critical for beta cell function (ABCC8, KCNJ11, HADH) and pituitary development (GLI2, NKX2-2, SHH) is significantly decreased with mutant Foxa2 compared with wild type [53 & ]. These two reports highlight an apparent new cause of hyperinsulinism that should be considered especially when pituitary deficiencies co-exist.
Turner syndrome
Hyperinsulinism appears to occur at higher rates in infants with turner syndrome than expected: 6/678 hyperinsulinism cases had turner syndrome, compared with 1 : 2500 newborns [54] . As in Kabuki syndrome, KDM6A haploinsufficiency may be implicated, as demonstrated by abnormalities of insulin release that occur in control human islets when treated with KDM6A inhibitor [54] .
VALUE OF A GENETIC DIAGNOSIS
Genetic diagnosis is important for prognostication, genetic counseling, and to anticipate the clinical course and screen for diabetes later in life in individuals with HNFs hyperinsulinism. But perhaps the most critical value of a genetic diagnosis is the ability to predict focal hyperinsulinism. The rapid identification of a K ATP mutation has been demonstrated [55] and can have significant clinical impact. In addition to anticipating diazoxide-unresponsiveness, if a K ATP mutation is found, whether the mutation is recessive and monoallelic, recessive and biallelic, or dominant can predict whether the disease occurs as a focal area of adenomatosis in the pancreas (focal hyperinsulinism) or as diffuse disease (diffuse hyperinsulinism) [7] . The potential to cure patients with focal hyperinsulinism with a limited pancreatic resection highlights the importance of genetic testing to avoid prolonged medical therapy and ongoing risk of hypoglycemia. The most common method of testing for hyperinsulinism mutations remains Sanger or Next Generation sequencing, but as whole exome sequencing becomes lower in cost, it may have a role in hyperinsulinism diagnosis [56 & ]. However, this technique would miss deep intronic mutations, which may also cause hyperinsulinism by pseudoexon activation [57] .
THERAPEUTIC OPTIONS
One of the major advances in the management of hyperinsulinism has been the development of 18FDOPA PET for localization of focal lesions prior to surgery, which has led to the ability to cure these cases [58] . (N.B. In the United States, 18FDOPA is used under an investigational IND.) Therefore, surgical resection of the lesion is the treatment of choice for focal hyperinsulinism. Current therapeutic options (Fig. 2) in nonfocal hyperinsulinism are limited. In cases unresponsive to all medical management, near-total pancreatectomy may be required. In cases of diazoxide-unresponsiveness, octreotide and longer-acting somatostatin analogs remain first-line therapy and are generally considered to be well tolerated and effective, although they are not approved for this indication in the United States [59 & ]. Unfortunately, a dose-dependent reduction in splanchnic blood flow may increase risk of necrotizing enterocolitis, limiting its use in neonates [60, 61 && ]. The most commonly recognized side effects of octreotide include transient transaminitis and asymptomatic gallbladder disease [62] . van der Steen et al. [63 && ] recently described an international experience with longer acting somatostatin analogs lanreotide and sandostatin-LAR. They found improved glycemic control in 89% of patients and recommended monitoring liver enzymes every 4-6 weeks and abdominal ultrasound every 3-6 months because of high prevalence of elevated liver enzymes (37%) and asymptomatic cholelithiasis.
Potential future therapies include GLP-1 receptor antagonists such as Exendin- (9- 
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